Sir Stephen Jackson (Steve)

Sir Stephen (Steve) Jackson is a distinguished scientist and executive in the field of biology and molecular research. Currently serving as Chief Research Officer at Insmed Innovation UK since August 2023, Jackson has extensive experience as a Founding Partner at Ahren Innovation Capital since July 2018 and as a Founding Scientist at Mission Therapeutics Ltd. since April 2011. A prominent academic, Jackson holds the position of Professor of Biology at the University of Cambridge since February 1995. Notable achievements include founding Adrestia Therapeutics Ltd. and serving as its Chief Scientific Officer until its acquisition by Insmed in 2023, as well as leading cancer research efforts as Head of Cancer Research UK Laboratories at the Gurdon Institute from 2004 to 2022. Jackson's previous roles include founding and leading scientific operations at KuDOS Pharmaceuticals and Mission Therapeutics, and contributions to the field have been supported by a PhD in Cell Biology from the University of California, Berkeley, and a BSc Hons from the University of Leeds.